RecruitingPhase 2NCT07586202

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Sponsor

Janssen Research & Development, LLC

Enrollment

68 participants

Start Date

Jul 28, 2026

Study Type

INTERVENTIONAL

Conditions

Carcinoma, Non-Small Cell Lung

Summary

The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Amivantamab, a drug called Carboplatin, and others for people with carcinoma, non-small cell lung. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmivantamab

Amivantamab will be administered.

DRUGLazertinib

Lazertinib will be administered.

DRUGCarboplatin

Carboplatin will be administered.

DRUGPemetrexed

Pemetrexed will be administered.

Locations(20)

City of Hope

Duarte, California, United States

City of Hope 1

Irvine, California, United States

Providence Cancer Center

Portland, Oregon, United States

Providence Oncology and Hematology Care Clinic Westside

Portland, Oregon, United States

Princess Margaret Hospital

Toronto, Ontario, Canada

Sichuan Cancer Hospital

Cheng Du Shi, China

West China Hospital Sichuan University

Chengdu, China

Guangdong Provincial People's Hospital

Guangzhou, China

Shandong Cancer Hospital

Jinan, China

Tianjin Chest Hospital

Tianjin, China

Kyungpook National University Chilgok Hospital

Buk Gu, South Korea

Pusan National University Hospital

Busan, South Korea

Samsung Medical Center

Seoul, South Korea

Korea University Guro Hospital

Seoul, South Korea

Hosp. Gral. Univ. Dr. Balmis

Alicante, Spain

Hosp. Gral. Univ. Gregorio Maranon

Madrid, Spain

Taichung Veterans General Hospital

Taichung, Taiwan

Chi Mei Medical Center Liouying Branch

Tainan, Taiwan

Taipei Medical University Hospital

Taipei, Taiwan

NTU Biomedical Park Hospital

Zhubei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07586202

Related Trials

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT0685577170 locations

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422239 locations

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

NCT0448683310 locations

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT0715429012 locations

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

NCT0722729873 locations